Cargando…

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration

Objectives: Elevated neurofilament light chain (NFL) levels within the cerebrospinal fluid (CSF) are a biomarker representing axonal neurodegeneration in rapid progressive neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). It is unclear to what extent the levels of NFL increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Pawlitzki, Marc, Schreiber, Stefanie, Bittner, Daniel, Kreipe, Julia, Leypoldt, Frank, Rupprecht, Klemens, Carare, Roxana O., Meuth, Sven G., Vielhaber, Stefan, Körtvélyessy, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315185/
https://www.ncbi.nlm.nih.gov/pubmed/30631300
http://dx.doi.org/10.3389/fneur.2018.01037
_version_ 1783384233505456128
author Pawlitzki, Marc
Schreiber, Stefanie
Bittner, Daniel
Kreipe, Julia
Leypoldt, Frank
Rupprecht, Klemens
Carare, Roxana O.
Meuth, Sven G.
Vielhaber, Stefan
Körtvélyessy, Peter
author_facet Pawlitzki, Marc
Schreiber, Stefanie
Bittner, Daniel
Kreipe, Julia
Leypoldt, Frank
Rupprecht, Klemens
Carare, Roxana O.
Meuth, Sven G.
Vielhaber, Stefan
Körtvélyessy, Peter
author_sort Pawlitzki, Marc
collection PubMed
description Objectives: Elevated neurofilament light chain (NFL) levels within the cerebrospinal fluid (CSF) are a biomarker representing axonal neurodegeneration in rapid progressive neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). It is unclear to what extent the levels of NFL increase in the CSF (CSF-NFL) in a chronic neuroinflammatory process with axonal neurodegeneration, as found in primary progressive multiple sclerosis (PPMS). Methods: We used a multicenter approach to statistically compare CSF-NFL levels between PPMS patients (n = 50), ALS patients (n = 50), and healthy controls (n = 50). Clinical findings, including disease duration, expanded disability status scale (EDSS), electrophysiological recordings such as visual evoked potentials or spinal and cerebral MRI, and previously administered treatment were selected as experimental parameters retrospectively. Results: Median [range] CSF-NFL concentrations in PPMS patients were significantly higher than in the controls [1724 (799–4275) pg/ml vs. 1202 (612–2934) pg/ml, p = 0.015], and significantly lower compared to ALS patients [1724 (799–4275) pg/ml vs. 10238 (2610–35138) pg/ml, p < 0.001]. There was no correlation between CSF-NFL and disease duration (p = 0.5), EDSS (p = 0.2) or treatment (p = 0.3). Conclusion: We conclude that CSF-NFL may mirror the proposed slow axonal degeneration in PPMS, but does not reflect the disease severity.
format Online
Article
Text
id pubmed-6315185
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63151852019-01-10 CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration Pawlitzki, Marc Schreiber, Stefanie Bittner, Daniel Kreipe, Julia Leypoldt, Frank Rupprecht, Klemens Carare, Roxana O. Meuth, Sven G. Vielhaber, Stefan Körtvélyessy, Peter Front Neurol Neurology Objectives: Elevated neurofilament light chain (NFL) levels within the cerebrospinal fluid (CSF) are a biomarker representing axonal neurodegeneration in rapid progressive neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). It is unclear to what extent the levels of NFL increase in the CSF (CSF-NFL) in a chronic neuroinflammatory process with axonal neurodegeneration, as found in primary progressive multiple sclerosis (PPMS). Methods: We used a multicenter approach to statistically compare CSF-NFL levels between PPMS patients (n = 50), ALS patients (n = 50), and healthy controls (n = 50). Clinical findings, including disease duration, expanded disability status scale (EDSS), electrophysiological recordings such as visual evoked potentials or spinal and cerebral MRI, and previously administered treatment were selected as experimental parameters retrospectively. Results: Median [range] CSF-NFL concentrations in PPMS patients were significantly higher than in the controls [1724 (799–4275) pg/ml vs. 1202 (612–2934) pg/ml, p = 0.015], and significantly lower compared to ALS patients [1724 (799–4275) pg/ml vs. 10238 (2610–35138) pg/ml, p < 0.001]. There was no correlation between CSF-NFL and disease duration (p = 0.5), EDSS (p = 0.2) or treatment (p = 0.3). Conclusion: We conclude that CSF-NFL may mirror the proposed slow axonal degeneration in PPMS, but does not reflect the disease severity. Frontiers Media S.A. 2018-12-14 /pmc/articles/PMC6315185/ /pubmed/30631300 http://dx.doi.org/10.3389/fneur.2018.01037 Text en Copyright © 2018 Pawlitzki, Schreiber, Bittner, Kreipe, Leypoldt, Rupprecht, Carare, Meuth, Vielhaber and Körtvélyessy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Pawlitzki, Marc
Schreiber, Stefanie
Bittner, Daniel
Kreipe, Julia
Leypoldt, Frank
Rupprecht, Klemens
Carare, Roxana O.
Meuth, Sven G.
Vielhaber, Stefan
Körtvélyessy, Peter
CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
title CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
title_full CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
title_fullStr CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
title_full_unstemmed CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
title_short CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
title_sort csf neurofilament light chain levels in primary progressive ms: signs of axonal neurodegeneration
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315185/
https://www.ncbi.nlm.nih.gov/pubmed/30631300
http://dx.doi.org/10.3389/fneur.2018.01037
work_keys_str_mv AT pawlitzkimarc csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT schreiberstefanie csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT bittnerdaniel csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT kreipejulia csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT leypoldtfrank csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT rupprechtklemens csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT carareroxanao csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT meuthsveng csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT vielhaberstefan csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration
AT kortvelyessypeter csfneurofilamentlightchainlevelsinprimaryprogressivemssignsofaxonalneurodegeneration